Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple doctor alert could prevent deadly pregnancy complication

NCT ID NCT07614893

Prevention Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether notifying obstetric clinicians when a pregnant patient is at high risk for preeclampsia increases the use of low-dose aspirin, which can help prevent the condition. Researchers will compare clinics that receive these alerts to those that continue usual care. The goal is to improve prevention of a leading cause of pregnancy-related illness and death.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clinician notification (behavioral intervention)
What this could lead to
If successful, this could increase the use of low-dose aspirin to prevent preeclampsia in high-risk pregnancies, reducing maternal illness and death.
What could go wrong
This is an implementation trial, not testing a new drug. It may not change doctor behavior significantly, and aspirin use still depends on individual clinical judgment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2027

An estimate. Start dates often move.

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Pregnant individuals receiving outpatient obstetric care at participating medical centers. * Age 18 years or older. * Currently pregnant and within 12 to 28 weeks' gestation * Identified as having elevated predicted risk for preeclampsia as defined by USPSTSF and ACOG criteria * Receiving care from a clinician, care team, or clinic participating in the randomized implementation trial. Exclusion Criteria: * Known contraindication to aspirin prophylaxis documented in the electronic health record. * Pregnancy beyond the prespecified gestational age window for aspirin prophylaxis implementation at the time of eligibility assessment. * Not receiving ongoing obstetric care at a participating site.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aspirin prophylaxis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertension, pregnancy-induced hypertensive disorder pregnancy disorder preeclampsia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aspirin prophylaxis Hypertensive disorders of pregnancy (HDP) Preeclampsia Pregnancy complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Mass General Brigham

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.